Monday, May 15, 2017
Since 2012, the nonprofit organization TransCelerate Biopharma has worked to develop a template protocol designed to cut costs and shorten timelines for industry-sponsored trials. Separately, the FDA and NIH have also spearheaded an effort to provide a template for all government-funded trials. Several years ago, the two groups began working together, and have now announced that their respective templates have been aligned to further streamline product development in the clinical research industry as a whole.
A new technology that is capable of transferring data from wearable devices to a cloud platform accessible to clinical study teams in real time is being put through its paces in several pilot programs around the world.
Synexus and Radiant Clinical Research will integrate operations, forming a global site network for clinical research. The network will operate under the Synexus name and encompass 185 sites in 11 countries, with access to over 100 million patients.
The need for an alternative to the paper-based clinical trial process is long overdue. Not only is the original method cost- and labor-intensive, but it can delay new drug development, as well. The first siteless technology model for clinical trial research was introduced last year, and since then studies in this area continue.
In a serious commitment to take some of the hit-and-miss out of current practices that impact the rollout of new drugs, Diaceutics and BioReference Laboratories have signed a five-year collaborative agreement.
Verily Life Sciences, a subsidiary of Google’s parent company Alphabet, has unveiled a new smartwatch for clinical research that can capture round-the-clock health data for large-scale and long-term studies.
Cancer is the therapeutic target of more than half of all clinical trials now, and yet, said Accelovance President and CEO Steve Trevisan, small companies trying to launch early phase trials on their promising young compounds in oncology have no good place to turn for quality handholding.
The Rehabilitation Institute of Chicago (RIC) has moved into a new research hospital facility and renamed itself the Shirley Ryan AbilityLab. The former RIC now occupies a $550 million, 1.2 million square foot facility located on prime real estate in downtown Chicago. The AbilityLab aims to create a setting in which research scientists, engineers and other specialists can work side-by-side with clinicians and patients to improve treatment. This approach is a departure from traditional methods of organizing clinical practice and research, and will serve as an experimental model for medical institutions to observe.
Historically, R&D has been driven by the bottom line: profits and hard patient outcomes. However, a new movement in the device and pharmaceutical research industry is focusing on the patient experience.